-+ 0.00%
-+ 0.00%
-+ 0.00%
Daewoong Pharma reports over 90% BTK, ITK target occupancy in Phase 1 plodicitinib trial
Share
Listen to the news
Daewoong Pharma reports over 90% BTK, ITK target occupancy in Phase 1 plodicitinib trial
  • Daewoong Pharma presented Phase 1 results for autoimmune drug candidate plodicitinib at ACR Convergence on Nov. 9, 2026.
  • The single-dose study in 44 healthy adults recorded no serious adverse events; all treatment-emergent adverse events were mild.
  • Results showed strong engagement with immune-cell targets, providing early evidence supporting further clinical development.
  • A multiple-dose study is underway, with Phase 1 completion targeted for the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daewoong Pharma published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611170353PR_NEWS_EURO_ND__EN99786) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending